LifeVantage Corporation ( NASDAQ: LFVN) Q2 2025 Earnings Conference Call February 5, 2025 4:30 PM ET Reed Anderson – Managing Director-ICR Steve Fife – President and Chief Executive Officer Carl Aure ...

SALT LAKE CITY - LifeVantage Corporation (NASDAQ:LFVN), a $271 million market cap player in the health and wellness sector with impressive 79% gross profit margins, today announced the successful ...

Human breast cancer cell lines-derived xenograft tumor explants assay was used to evaluate the compound’s efficacy and to assess the induction of methuosis via NRF2 activation by tanshinlactone.

including its Protandim® product line, LifeVantage® Omega+ and ProBio dietary supplements, the TrueScience® line of Nrf2 infused skin care and hair care products, Petandim® for Dogs ...

Moreover, LifeVantage released a study showing the combined use of two of its products, Protandim® Nrf2 Synergizer® and MindBody GLP-1 System™, activates additional genes linked to organ health.

LifeVantage (LFVN) announced the results of a third-party cell study on the synergistic impact of Protandim Nrf2 Synergizer and the MindBody GLP-1 System. The findings reveal that when used ...

Results from a third-party study revealed significant synergistic benefits of the MindBody GLP-1 System™ combined with Protandim® Nrf2 Synergizer®, indicating improved organ health ...

today announced the results of a groundbreaking third-party cell study on the synergistic impact of Protandim ® Nrf2 Synergizer ® and the MindBody GLP-1 System ™. The findings reveal that when ...